forbes semaglutide Last week's expiry of the patent for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions Semaglutide loses market share to
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

























